Le Lézard
Classified in: Health, Covid-19 virus
Subjects: MAV, CFG

Media Advisory - Prime Minister's itinerary for Monday, March 30, 2020


OTTAWA, March 29, 2020 /CNW/ -

Note: All times local

 

Ottawa, Ontario



11:15 a.m.

The Prime Minister will address Canadians on the COVID-19 situation, and a media availability will follow.




Rideau Cottage


1 Sussex Drive




Notes for media:




  • Open coverage
  • Media are asked to arrive to the Princess Anne Entrance no later than 10:45 a.m. and to make their way to the P1 Gate once on the grounds.
  • Media wishing to cover the event must be accredited with the Parliamentary Press Gallery.
  • Journalists can dial in to listen and ask questions to the Prime Minister.
  • Participant dial-in numbers:
    Local: 613-960-7519
    Toll-free: 1-877-413-4814
    Pass code: 7740118#

 

This document is also available at http://pm.gc.ca

SOURCE Prime Minister's Office


These press releases may also interest you

at 08:03
The American Red Cross celebrates The Church of Jesus Christ of Latter-day Saints, headquartered in Salt Lake City, for its substantial donation of $7.35 million. The gift will help purchase blood equipment and biomedical emergency vehicles and will...

at 08:00
A Canada-wide Settlement Agreement was recently reached in a class action against Cook (Canada) Inc., Cook Incorporated, and William Cook Europe APS ("Cook") related to certain inferior vena cava filter products ("IVC Filter Products") marketed and...

at 08:00
Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that the US Food and Drug...

at 08:00
Key Proteo, a pioneering proteomics diagnostics company specializing in the enhanced early detection of rare but treatable genetic disorders, today announced that it has submitted a de novo classification request to the U.S. Food and Drug...

at 08:00
Human Immunology Biosciences (HI-Biotm), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that two abstracts have been accepted for oral presentation at the...

at 08:00
PassPort Technologies, Inc. (PPTI), based in San Diego, a clinical-stage drug and medical device development company, today announced positive interim results from the Phase 1 (Part A) clinical trial of Zolmitriptan PassPort® utilizing its...



News published on and distributed by: